Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative study of TACE regimens containing oxaliplatin or gemcitabine for unresectable hepatocellular carcinoma
ChiCTR-TNRC-08000079Phase 2Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Mar 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, gemcitabine and floxuridine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: time to progression. Started Mar 2007; status: completed.
02
Drugs
oxaliplatingemcitabinefloxuridine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TNRC-08000079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNRC-08000079.